Cite
HARVARD Citation
Satake, H. et al. (2020). Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). Oncologist. pp. e1855-e1863. [Online].